Given the limited efficacy of conventional ICIs targeting PD-1, PD-L1, and CTLA-4 in mUM, there is an urgent need to explore novel immune regulatory pathways that contribute to tumor immune evasion. This evidence concerns the gene CTLA4 and neoplasm.